EGFR and non-small cell lung carcinoma: On the contrary, EGFR-mutant, HER2-mutant, ALK, ROS1, RET, and MET alterations in NSCLC have limited benefit from ICB.121 EGFR-mutant NSCLC performs a non-inflamed immune phenotype due to PKCδ, a gatekeeper of immune haemostasis.